News
HNSBF
2.900
NaN%
--
Hansa Biopharma Raises USD 30 Million via Convertible Notes to Back U.S. Imlifidase Launch
TipRanks · 03/20 07:36
Hansa Biopharma to Present Commercial Strategy at Redeye Life Science Event
TipRanks · 03/13 11:32
Hansa Biopharma to Spotlight Immunomodulatory Platform at DNB Carnegie Healthcare Conference
TipRanks · 03/10 09:33
Hansa Biopharma leadership to spotlight growth strategy at LSX Investival USA
TipRanks · 03/09 09:02
Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference
TipRanks · 03/06 17:03
Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
TipRanks · 03/05 18:15
Hansa Biopharma Secures FDA PDUFA Date for Imlifidase in High-Risk Kidney Transplant Patients
TipRanks · 03/04 22:03
Hansa Biopharma to Present Corporate Strategy at TD Cowen Health Care Conference
TipRanks · 02/23 16:33
Imlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma
TipRanks · 02/19 11:16
Hansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy
TipRanks · 02/18 19:02
Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright
TipRanks · 02/12 11:05
Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
TipRanks · 02/12 00:02
Hansa Biopharma reports Q4 results
Seeking Alpha · 02/11 10:05
Hansa Biopharma Delivers Strong Q4 Growth and Files FDA Application for Imlifidase
TipRanks · 02/11 06:33
Hansa Biopharma Sets February Date for 2025 Year-End Results Call
TipRanks · 01/26 11:34
Hansa Biopharma Wins 2025 SwedenBIO Award as Late-Stage Pipeline Advances
TipRanks · 01/22 13:03
Hansa Biopharma initiated with an Outperform at Wedbush
TipRanks · 01/07 12:46
Hansa Biopharma Files FDA BLA for Imlifidase in High-Risk Kidney Transplant Patients
TipRanks · 12/19/2025 20:02
Hansa Biopharma to Present at J.P. Morgan Healthcare Conference to Boost Investor Visibility
TipRanks · 12/19/2025 11:04
Hansa Biopharma price target lowered to SEK 111 from SEK 132 at H.C. Wainwright
TipRanks · 12/17/2025 11:11
More
Webull provides a variety of real-time HNSBF stock news. You can receive the latest news about Hansa Medical AB through multiple platforms. This information may help you make smarter investment decisions.
About HNSBF
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.